Citadel Advisors
DTIL icon

Citadel Advisors’s Precision BioSciences DTIL Stock Holding History

Citadel Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-150
Closed -$1.64K – 14716
2023
Q4 		$1.64K Sell
150
-47
-24% -$507 ﹤0.01% 13795
2023
Q3 		$2.01K Sell
197
-113
-36% -$1.74K ﹤0.01% 13771
2023
Q2 		$4.89K Sell
310
-40
-11% -$915 ﹤0.01% 13554
2023
Q1 		$7.91K Sell
350
-50
-13% -$1.65K ﹤0.01% 13691
2022
Q4 		$14.3K Sell
400
-120
-23% -$4.74K ﹤0.01% 13402
2022
Q3 		$20K Buy
+520
New +$24.7K ﹤0.01% 12071
2021
Q4 		– Sell
-1,330
Closed -$460K – 13971
2021
Q3 		$460K Sell
1,330
-200
-13% -$67.8K ﹤0.01% 10078
2021
Q2 		$575K Buy
1,530
+883
+136% +$265K ﹤0.01% 9738
2021
Q1 		$201K Sell
647
-113
-15% -$39.6K ﹤0.01% 11690
2020
Q4 		$190K Sell
760
-140
-16% -$34.3K ﹤0.01% 9775
2020
Q3 		$166K Buy
900
+130
+17% +$25.9K ﹤0.01% 8945
2020
Q2 		$192K Buy
770
+143
+23% +$31.3K ﹤0.01% 8560
2020
Q1 		$113K Sell
627
-36
-5% -$9.42K ﹤0.01% 8547
2019
Q4 		$276K Buy
+663
New +$208K ﹤0.01% 7714

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors's DTIL Position: Q1 2026 in Review

Citadel Advisors increased its Precision BioSciences (DTIL) stake by 636% in Q1 2026, buying an estimated $462K and bringing the position to 115,952 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #8703.

Citadel Advisors first reported a position in DTIL in Q1 2019 and has held it in 27 quarters since. The position peaked at $12.6M in Q4 2020. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Citadel Advisors held 115,952 shares of Precision BioSciences worth $638K as of Q1 2026.
  • Citadel Advisors bought 100,204 Precision BioSciences shares in Q1 2026, an estimated $462K.
  • Precision BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8703 holding.
  • Citadel Advisors first reported a position in Precision BioSciences in Q1 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Precision BioSciences position peaked at $12.6M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.